Stay updated on CTX130 in Relapsed/Refractory T/B Malignancies Clinical Trial

Sign up to get notified when there's something new on the CTX130 in Relapsed/Refractory T/B Malignancies Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the CTX130 in Relapsed/Refractory T/B Malignancies Clinical Trial page

  1. Check
    4 days ago
    No Change Detected
  2. Check
    11 days ago
    Change Detected
    Summary
    The record describes the Phase 1 CTX130 study for relapsed or refractory T- or B-cell malignancies, including its terminated status, eligibility criteria, study locations, interventions, and outcome measures.
    Difference
    44%
    Check dated 2026-11-07T14:48:20.000Z thumbnail image
  3. Check
    18 days ago
    Change Detected
    Summary
    The footer now identifies the ClinicalTrials.gov site revision as v3.8.0 instead of v3.7.2.
    Difference
    0.2%
    Check dated 2026-10-31T15:36:55.000Z thumbnail image
  4. Check
    25 days ago
    Change Detected
    Summary
    A site-wide NIH notice announces a transition in terminology from “Artificial Intelligence” to “Super Intelligence” across NIH content.
    Difference
    1%
    Check dated 2026-10-24T14:59:23.000Z thumbnail image
  5. Check
    32 days ago
    Change Detected
    Summary
    The footer’s site revision identifier changed from v3.7.1 to v3.7.2; the page content remains a 403 error.
    Difference
    0.2%
    Check dated 2026-10-17T14:47:26.000Z thumbnail image
  6. Check
    39 days ago
    Change Detected
    Summary
    The page remains a 403 Forbidden error page. Its footer revision label changes from v3.7.0 to v3.7.1.
    Difference
    0.2%
    Check dated 2026-10-10T15:50:34.000Z thumbnail image
  7. Check
    60 days ago
    Change Detected
    Summary
    Now the page displays a 403 Forbidden error, blocking access to the study record instead of showing the study details. This indicates an access-control issue rather than an update to the study information.
    Difference
    17%
    Check dated 2026-09-19T19:06:06.000Z thumbnail image

Stay in the know with updates to CTX130 in Relapsed/Refractory T/B Malignancies Clinical Trial

Enter your email address, and we'll notify you when there's something new on the CTX130 in Relapsed/Refractory T/B Malignancies Clinical Trial page.